Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Q2 XDEMVY sales rise 69% to $173.9 million; 2026 sales guidance raised

Positive Impact 4 of 5 earnings Written later

Tarsus Pharmaceuticals reported second-quarter 2026 XDEMVY net product sales of $173.9 million, up from $102.7 million a year earlier, and raised its full-year 2026 XDEMVY sales guidance to $685-705 million. The company also reported a smaller net loss, and it has a pending acquisition of Alkeus Pharmaceuticals along with a $125 million private placement.

Key points

  • Q2 2026 net product sales were $173.9 million, compared with $102.7 million in Q2 2025.
  • Full-year 2026 XDEMVY net product sales guidance raised to $685-705 million.
  • Q2 2026 net loss was $18.6 million, or $(0.43) per share, compared with $20.3 million, or $(0.48) per share, a year earlier.
  • Pending acquisition of Alkeus Pharmaceuticals; $125 million private placement priced. Cash and marketable securities were $449.7 million at June 30, 2026.

The filing

CompanyTarsus Pharmaceuticals, Inc. (TARS)
Form8-K, current report
Filed with the SECAug 6, 2026, 7:23 AM ET
Accession number0001819790-26-000063

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.